BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 22766739)

  • 1. Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression.
    Beckett TL; Webb RL; Niedowicz DM; Holler CJ; Matveev S; Baig I; LeVine H; Keller JN; Murphy MP
    J Alzheimers Dis; 2012; 32(1):127-38. PubMed ID: 22766739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.
    Klunk WE; Lopresti BJ; Ikonomovic MD; Lefterov IM; Koldamova RP; Abrahamson EE; Debnath ML; Holt DP; Huang GF; Shao L; DeKosky ST; Price JC; Mathis CA
    J Neurosci; 2005 Nov; 25(46):10598-606. PubMed ID: 16291932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease.
    Bunai T; Kakimoto A; Yoshikawa E; Terada T; Ouchi Y
    J Alzheimers Dis; 2019; 69(2):529-538. PubMed ID: 31104023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease.
    Rosen RF; Ciliax BJ; Wingo TS; Gearing M; Dooyema J; Lah JJ; Ghiso JA; LeVine H; Walker LC
    Acta Neuropathol; 2010 Feb; 119(2):221-33. PubMed ID: 19690877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A distinct subfraction of Aβ is responsible for the high-affinity Pittsburgh compound B-binding site in Alzheimer's disease brain.
    Matveev SV; Spielmann HP; Metts BM; Chen J; Onono F; Zhu H; Scheff SW; Walker LC; LeVine H
    J Neurochem; 2014 Nov; 131(3):356-68. PubMed ID: 24995708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S; Wakebe D
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disrupted Intrinsic Networks Link Amyloid-β Pathology and Impaired Cognition in Prodromal Alzheimer's Disease.
    Koch K; Myers NE; Göttler J; Pasquini L; Grimmer T; Förster S; Manoliu A; Neitzel J; Kurz A; Förstl H; Riedl V; Wohlschläger AM; Drzezga A; Sorg C
    Cereb Cortex; 2015 Dec; 25(12):4678-88. PubMed ID: 24996404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease.
    Vannini P; Amariglio R; Hanseeuw B; Johnson KA; McLaren DG; Chhatwal J; Pascual-Leone A; Rentz D; Sperling RA
    Neuropsychologia; 2017 May; 99():343-349. PubMed ID: 28385579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease.
    Niedowicz DM; Beckett TL; Matveev S; Weidner AM; Baig I; Kryscio RJ; Mendiondo MS; LeVine H; Keller JN; Murphy MP
    Ann Neurol; 2012 Oct; 72(4):564-70. PubMed ID: 23109151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcortical and Cortical Regions of Amyloid-β Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients.
    Almkvist O; Brüggen K; Nordberg A
    J Alzheimers Dis; 2021; 81(4):1613-1624. PubMed ID: 33967046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging of brain amyloid in dementia: a review.
    Quigley H; Colloby SJ; O'Brien JT
    Int J Geriatr Psychiatry; 2011 Oct; 26(10):991-9. PubMed ID: 21905095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.
    Zhang N; Zhang L; Li Y; Gordon ML; Cai L; Wang Y; Xing M; Cheng Y
    J Alzheimers Dis; 2017; 60(1):87-95. PubMed ID: 28777752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques.
    Driscoll I; Troncoso JC; Rudow G; Sojkova J; Pletnikova O; Zhou Y; Kraut MA; Ferrucci L; Mathis CA; Klunk WE; O'Brien RJ; Davatzikos C; Wong DF; Resnick SM
    Acta Neuropathol; 2012 Dec; 124(6):823-31. PubMed ID: 22864813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease Dementia.
    Marshall GA; Gatchel JR; Donovan NJ; Muniz MC; Schultz AP; Becker JA; Chhatwal JP; Hanseeuw BJ; Papp KV; Amariglio RE; Rentz DM; Sperling RA; Johnson KA
    J Alzheimers Dis; 2019; 67(2):757-768. PubMed ID: 30689584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.
    Ikonomovic MD; Abrahamson EE; Price JC; Hamilton RL; Mathis CA; Paljug WR; Debnath ML; Cohen AD; Mizukami K; DeKosky ST; Lopez OL; Klunk WE
    Acta Neuropathol; 2012 Mar; 123(3):433-47. PubMed ID: 22271153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnestic Mild Cognitive Impairment.
    Wang Y; Lou F; Li Y; Liu F; Wang Y; Cai L; Gordon ML; Zhang Y; Zhang N
    Curr Alzheimer Res; 2021; 18(6):523-532. PubMed ID: 34598664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease.
    Verdile G; Laws SM; Henley D; Ames D; Bush AI; Ellis KA; Faux NG; Gupta VB; Li QX; Masters CL; Pike KE; Rowe CC; Szoeke C; Taddei K; Villemagne VL; Martins RN;
    Mol Psychiatry; 2014 Jan; 19(1):69-75. PubMed ID: 23089633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.